A Phase 3 interventional study of Cenegermin and Vehicle in Non-Arteritic Anterior Ischemic Optic Neuropathy, sponsored by Dompé Farmaceutici S.p.A. Recruiting at 38 sites in 4 countries. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Dompé Farmaceutici S.p.A · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Optic Neuropathy, Ischemic with a site in United States — 3 open to participants now, 3 under way, 1 of them phase 3. Optic Neuropathy, Ischemic · United States.
Among the 20 studies in Optic Neuropathy, Ischemic with a site in United States, this one is the 5th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is the only one in phase 3, and was the 20th registered.
55 studies on the registry are indexed under Optic Neuropathy, Ischemic; 11 are open to participants now.
Browse Optic Neuropathy, Ischemic studies →3 of the 20 studies in Optic Neuropathy, Ischemic with a site in United States are open now. Recruiting first, the newest first:
Randy Kardon · Sites in United States
Ages 18–99 · Healthy volunteers
MD Stem Cells · Sites in United States, Austria, United Arab Emirates
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Optic Neuropathy, Ischemic studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 2 · Phase 4 2
First in 1994; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 272 is above the median of 40 across 35 interventional studies indexed under Optic Neuropathy, Ischemic.
Median enrollment 73 across the 14 interventional studies, 35 across the 5 observational. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 20 have an industry lead sponsor. The 10 most frequent:
Dompé Farmaceutici S.p.A is the lead sponsor of 52 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 18 (100%) have results posted.
Dompé Farmaceutici S.p.A has 1 study filed under Optic Neuropathy, Ischemic — fewer than ten, so there is no comparison to draw.
2 of the studies in Optic Neuropathy, Ischemic with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07453888Phase 3Dompé Farmaceutici S.p.AEfficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) | 2027-09 |
| NCT03011541MD Stem CellsStem Cell Ophthalmology Treatment Study II | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 20 studies in Optic Neuropathy, Ischemic with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 3, randomized, multicenter, vehicle-controlled, double-masked study to evaluate the efficacy and safety of intranasal cenegermin compared with vehicle control in adult participants with NAION. Approximately 272 participants who meet all eligibility criteria will be randomly assigned in a 1:1 ratio to receive either cenegermin treatment (Group 1) or the vehicle control (Group 2).
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Additional inclusion/exclusion criteria apply, as defined in the protocol.
Participants will be administered with cenegermin spray in each nostril.
Drug: Cenegermin
Participants will be administered with vehicle spray in each nostril.
Other: Vehicle
Cenegermin is administered intranasally.
Vehicle spray is administered intranasally.
Achievement of ≥ 15 letter increase in Best Corrected Visual Acuity (BCVA), assessed in each individual participant, measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart
Improvement in visual acuity defined as a \>=15 letter increase in BCVA using ETDRS chart.
Time frame: Baseline to Week 24
Change from baseline in visual field mean sensitivity in decibels
Change from baseline in visual field mean sensitivity in decibels will be analyzed
Time frame: Baseline through Week 24
Change from baseline in BCVA as measured by the ETDRS chart
Time frame: Baseline through Week 24
Change from baseline in visual field mean sensitivity, in a prespecified region consisting of at least 5 separate loci on visual field testing
Change from baseline in mean sensitivity at week 24 in loci prespecified at baseline will be analyzed.
Time frame: Baseline through Week 24
Change from baseline in ganglion cell layer-inner plexiform layer (GCL-IPL) thickness (micrometer [μm]) on optical coherence tomography (OCT).
Change from baseline in GCL-IPL thickness on optical coherence tomography will be analyzed.
Time frame: Baseline through Week 24
Incidence of ocular and non-ocular adverse events
Number of participants with ocular and non-ocular adverse events will be assessed.
Time frame: Through Week 24
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Sep 2027, 14 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cenegermin